Simple and Practical Mental Health

The BEST resource for mental health clinicians

  • REVIEWS
  • MENUS
  • RESOURCES
    • Side effect handouts
    • Patient handouts: Main page
    • How to find treatment resources
    • Rating scales and questionnaires for mental health clinicians
    • BEST books
    • BEST apps/ websites
  • NEWS
  • QUESTIONS?
  • DAILY EMAILS
  • FAQ
  • LOG IN
  • JOIN

What does “treatment-resistant depression” in the indication for esketamine (Spravato®) mean?

By Rajnish Mago, MD (bio) Esketamine nasal spray (brand name Spravato®) was approved by the FDA in March 2019. As of January 2020, the wording in the Prescribing Information notes that it is “indicated, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults.” That’s pretty vague! I was really…

This content is for Monthly Membership and Yearly Membership members only.
Register
Already a member? Log in here

Share this:

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email

Follow us on social media

  • Facebook
  • LinkedIn
  • Twitter

Copyright 2016 to 2025: Simple and Practical Medical Education, LLC. All rights reserved.